Alternative Strategies of Reducing MYC Expression for the Treatment of Cancers

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• MYC is a key oncogene implicated in approximately 70% of human cancers, regulating critical cellular processes.
• Dysregulation of MYC drives cancer progression, making it a significant therapeutic target.
• Direct targeting of MYC is challenging due to its disordered structure and nuclear localization.

Purpose of the Study:

• To review the structure, biological functions, and cancer relevance of MYC.
• To evaluate current and emerging therapeutic strategies for MYC-driven cancers.
• To highlight innovative approaches including dual-targeted agents and PROTAC technology.

Main Methods:

• Literature review and synthesis of current research on MYC.
• Analysis of therapeutic strategies targeting MYC expression and function.
• Evaluation of proteolysis-targeting chimeras (PROTACs) for MYC degradation.

Main Results:

• MYC's role in cell proliferation, differentiation, metabolism, and apoptosis is critical in tumorigenesis.
• Existing direct MYC-targeting therapies are limited, necessitating indirect strategies.
• Dual-targeted agents and various PROTAC platforms show potential for effective MYC suppression.

Conclusions:

• Targeting MYC dysregulation is a vital strategy for cancer treatment.
• Innovative approaches like dual-targeting agents and PROTACs offer new hope for "undruggable" targets like MYC.
• Further development of these strategies is crucial for advancing cancer therapeutics.